Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Ç÷縶Á¦´ÒÀÇ °æºñ Åõ¿©

Clinical Trial of Nasal Flumazenil Administration

´ëÇѼҾÆÄ¡°úÇÐȸÁö 2001³â 28±Ç 3È£ p.441 ~ 446
È«¼öÁø, ±èÇöÁ¤, ¿°±¤¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
È«¼öÁø ( Hong Soo-Jin ) - ¼­¿ï´ëÇб³ Ä¡°ú´ëÇÐ Ä¡°ú¸¶Ãë°úÇб³½Ç
±èÇöÁ¤ ( Kim Hyun-Jeong ) - ¼­¿ï´ëÇб³ Ä¡°ú´ëÇÐ Ä¡°ú¸¶Ãë°úÇб³½Ç
¿°±¤¿ø ( Yeom Kwang-Won ) - ¼­¿ï´ëÇб³ Ä¡°ú´ëÇÐ Ä¡°ú¸¶Ãë°úÇб³½Ç

Abstract

Ç÷縶Á¦´ÒÀº º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ°è ¾à¹°ÀÇ ±æÇ×Á¦·Î¼­, Á¤Áַθ¦ ÅëÇÏ¿© ü³»¿¡ Åõ¿©µÈ´Ù. ±×·¯³ª Á¤Áַΰ¡ È®º¸µÇÁö ¾ÊÀº »óÅ¿¡¼­ Ç÷縶Á¦´ÒÀÇ ±æÇ×ÀÛ¿ëÀÌ ÇÊ¿äÇÒ ¶§¿¡´Â Á¤ÁÖ·Î ÀÌ¿ÜÀÇ Ã¼³» Åõ¿©·Î°¡ ¿ä±¸µÈ´Ù. º» ¿¬±¸¿¡¼­´Â ¹Ì´ÙÁ¹¶÷À¸·Î ½ÉÁøÁ¤À» À¯µµÇÑ ÈÄ Ç÷縶Á¦´ÒÀÇ °æºñÅõ¿©·Î ÀÎÇÑ ÀÇ½Ä »óÅÂÀÇ °¡¿ªÀ» ÀÓ»ó½ÃÇèÇÏ¿´´Ù. ¼ºÀγ²³à 25¸íÀ» ´ë»óÀ¸·Î ¹Ì´ÙÁ¹¶÷À» ¼Ò·®¾¿ 0.08mg/kg±îÁö Åõ¿©ÇÏ¿© ÀǽļҽÇÀ» À¯µµÇÏ¿´´Ù. ¹Ì´ÙÁ¹¶÷ Åõ¿© 10ºÐ ÈÄ Ç÷縶Á¦´Ò 0.5mgÀ» 1ºÐ µ¿¾È ÁÖ»ç±â¸¦ ÀÌ¿ëÇÏ¿© õõÈ÷ °æºñÅõ¿©ÇÏ¿´´Ù. ȯÀÚ°¨½Ã¿¡´Â ½ÉÀüµµ, ÀÚµ¿Ç÷¾Ð°è, È£±â¸» ÀÌ»êÈ­ ź¼ÒºÐ¾Ð ¹é¹Ú»ê¼ÒÆ÷È­µµ µîÀ» »ç¿ëÇÏ¿´´Ù. ÁøÁ¤ÀÇ Á¤µµ´Â ÁøÁ¤Á¡¼ö¿Í ³úÆÄ°¨½Ã¸¦ ÀÌ¿ëÇÑ bispectral index·Î Æò°¡ÇÏ¿´´Ù. Ç÷縶Á¦´Ò Åõ¿© Á÷Àü¿¡ ¹Ì´ÙÁ¹¶÷°ú Ç÷縶Á¦´ÒÀÇ Ç÷Áß ³óµµ¸¦, Ç÷縶Á¦´Ò Åõ¿© ÈÄ 5, 10, ¹× 20ºÐ ÈÄ¿¡ Ç÷û Ç÷縶Á¦´Ò ³óµµ¸¦ ÃøÁ¤ÇÏ¿´´Ù. Ç÷縶Á¦´ÒÀÇ °æºñÅõ¿© ÈÄ ¿ÏÀüÇÑ ±æÇ×È¿°ú¸¦ ³ªÅ¸³½ °æ¿ì´Â Àüü 25¸í Áß 2¸íÀ̾ú´Ù. Ç÷û Ç÷縶Á¦´ÒÀÇ ³óµµ´Â Åõ¿© 10ºÐ ÈÄ¿¡ ÃÖ°íÄ¡¿¡ µµ´ÞÇÏ¿´°í, 20ºÐ°£ Áö¼ÓµÇ¾ú´Ù. ÁøÁ¤Á¡¼ö´Â ¹Ì´ÙÁ¹¶÷ Åõ¿© ÈÄ Áõ°¡ÇÑ µÚ Ç÷縶Á¦´Ò Åõ¿© ÈÄ À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ¿´´Ù(p<0.05). ±×·¯³ª bispectral index´Â ¹Ì´ÙÁ¹¶÷ Åõ¿© ÈÄ ½Ã°£°æ°ú¿¡ µû¶ó À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ¿´À¸³ª, Ç÷縶Á¦´Ò Åõ¿©ÈÄ¿¡´Â À¯ÀÇ ÇÑ º¯È­¸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù. °á·ÐÀûÀ¸·Î 0.1m/ml ³óµµÀÇ Ç÷縶Á¦´Ò 0.5mg °æºñÅõ¿©´Â ¹Ì´ÙÁ¹¶÷À¸·Î À¯µµµÈ ½ÉÁøÁ¤½Ã ±æÇ×È¿°ú°¡ ¿ÏÀüÇÏÁö ¾Ê¾ÒÀ¸³ª, °æºñÅõ¿© ÈÄ Ç÷¾×¿¡¼­ Ç÷縶Á¦´ÒÀÇ ³óµµÃøÁ¤ÀÌ °¡´ÉÇÏ¿´´Ù´Â °á°ú´Â ÀÓ»ó»ç¿ë °¡´É¼ºÀ» Á¦½ÃÇϸç Á¤ÁÖ¿ëÀ¸·Î »ç¿ëµÇ´Â Ç÷縶Á¦´ÒÀÇ ³óµµ°¡ ³·Àº Á¡À» º¸¿ÏÇÒ ¼ö ÀÖ´Â »õ·Î¿î Á¦ÀçÀÇ °í¾ÈÀÌ ÇÊ¿äÇÏ´Ù°í »ý°¢µÈ´Ù.lis ´Üµ¶ ¹è¾ç½Ã ml´ç À̾úÀ¸³ª, S. oralis¿Í 4ÁÖÀÇ ºÐ¸®±ÕÁÖ È¥ÇÕ ¹è¾ç½Ã S. oralis´Â ³»Áö À¸·Î °¨¼ÒµÇ¾ú´Ù. 6. 3ÁÖÀÇ ºÐ¸®±ÕÁÖ·Î ºÎÅÍ ¾à 60 kbÀÇ plasmid¸¦ ºÐ¸® ÇÒ ¼ö ÀÖ¾ú´Ù. ÀÌ»óÀÇ °á°ú¸¦ Á¾ÇÕÇÏ¸é ±¸°­¿¡¼­ ºÐ¸®µÈ E. durans´Â S. mutansÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ¿© ÀΰøÄ¡Å Çü¼ºÀ» ÀúÁöÇÏ¿´°í, S. oralisÀÇ Áõ½ÄÀº ¾à°£ ¾ïÁ¦ÇÏ¿´´Ù.5), II±º°ú I±º°£¿¡´Â À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù (p>0.05). º» ½ÇÇè¿¡¼­ ½ÃµµÇÑ µÎ °¡Áö ÁøÁ¤¿ä¹ýÀÌ ºñ±³Àû ³ôÀº ÀÓ»óÀû Ä¡·á ¼º°ø·ü(II±º : 97.14%, III±º : 88.57%)À» º¸¿© ¸¸Á·ÇÒ ¸¸ÇÑ °á°ú¸¦ ³ªÅ¸³½ °ÍÀ¸·Î Æò°¡µÇ¾ú´Ù.tosan filmº¸´Ù Å« ¼öÁõ±â Åõ°úµµ¸¦ º¸¿´´Ù.ÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù.y tissue layer thinningÀº 3 ±º¸ðµÎ¿¡¼­ °üÂûµÇ¾ú°í Ç×¾Ï 3 ÀϱºÀÌ °¡Àå ½ÉÇÏ°Ô ³ªÅ¸³µ´Ù. ÀÌ»óÀÇ ½ÇÇè°á°ú¸¦ º¸¸é ¼úÀü Ç×¾ÏÁ¦Åõ¿©°¡ Ãʱ⿡ ½ÃÇàÇÑ °æ¿ì¿¡´Â Á¶Á÷ÀÇ Ä¡À¯¿¡ Ãʱâ 5 ÀÏÁ¤µµ±îÁö´Â ¿µÇâÀ» ¹ÌÄ¡³ª 7 ÀÏÀÌ Áö³ª¸é Á¤»ó¹üÁַΠȸº¹ÇÔÀ» ¾Ë¼ö ÀÖ¾ú°í ½ÇÇè°á°ú Ç×¾ÏÁ¦ Åõ¿©ÈÄ 3 ÀÏ° ÇÇÆÇ Çü¼ºÇÑ ±º¿¡¼­ ÇÇÆÇÄ¡À¯°¡ ´Ê¾îÁø °ÍÀ¸·Î °üÂûµÇ¾î ÀÎü¿¡¼­ Ç×¾Ï Åõ¿©ÈÄ ¼ö¼ú½Ã±â´Â ÀÎü¸é¿ª°è°¡ ȸº¹ÇÏ´Â ½Ã±â¸¦ 3ÁÖÀÌ»ó °æ°úÈÄ Àû¾îµµ 4ÁÖ° ¼ö¼ú½Ã±â¸¦ Á¤ÇÏ´Â °ÍÀÌ À¯¸®Çϸ®¶ó »ý°¢µÇ¾ú´Ù.ÇÑ º¹ÇÕ·¹ÁøÀº °³¹ßÀÇ Ãʱâ´Ü°èÀ̸ç, ¹°¼ºÀÇ Áõ°¡¸¦ À§ÇÑ ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù.¶Ç ´Ù¸¥ ¾à¹°ÀÎ glycyrrhetinic acid()µµ CCh ÀÚ±ØÀ¸·Î ÀÎÇÑ Å¸¾×ºÐºñ¸¦ ¾ïÁ¦ÇÏ¿´´Ù.

Flumazenil is a competitive antagonist of benzodiazepines. It is usually administered intravenously. However, if the intravenous route is not available then other routes of drug administration should be considered. This study was designed to evaluate the reversal effects of flumazenil after nasal administration. Twenty-five young, healthy adult volunteers participated in this clinical trial. The dosage of 0.08mg/kg midazolam was administered intravenously to induce deep sedation. Ten minutes after midazolam administration, 0.5mg of flumazenil was dropped nasally, over a period of one minute. Blood samples were taken to measure the concentration of midazolam and flumazenil at 0, 5, 10, and 20min after nasal administration of flumazenil, using High Performance Liquid Chromatography. The degree of sedation was evaluated with sedation score and bispectral index (BIS), Statistical analysis was performed by multivariate ANOVA and correlation analysis (P<0.05). Peak serum flumazenil concentration was reached in 10min. Sedation score decreased after midazolam administration and showed a significant increase after flumazenil administration. However, BIS decreased during the first 10min after midazolam administration and then no significant changes after flumazenil administration. There were two instances representing rapid and complete reversal of midazolam after intranasal administration of flumazenil. In conclusion, intranasal flumazenil administration may be effective in some patients when intravenous route is not available in condition of benzodiazepine overdose.

Å°¿öµå

Ç÷縶Á¦´Ò;°æºñÅõ¿©;¹Ì´ÙÁ¹¶÷;Å©·Î¸¶Åä±×·¡ÇÇ
flumazenil;intranasal administration;benzodiazepines;chromatography

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI